,50 Our group and others have recently developed a CD37-targeting CAR T cell-based therapy20,31,51 mirroring the CD19CAR T cell approach described for the treatment of B cell leukemia, B cell lymphoma,26,29 and T cell lymphoma.31 This evidence concerns the gene CD37 and T-cell non-Hodgkin lymphoma.